Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IGBA Welcomes Regional Association From Balkans

As Serbia And Montenegro Representative Genezis Joins IGBA

Executive Summary

To extend its representation in Europe, IGBA has welcomed the generic and biosimilar drug association of Serbia and Montenegro – Genezis – to the global off-patent industry body.

You may also be interested in...



Kelix Strikes A Deal To Acquire 14 Oncology Injectables

Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.

Cipla And mAbxience Partner For Essential Biosimilars In South Africa

Cipla has partnered with mAbxience to supply oncology and respiratory-related biosimilars on the WHO model list of essential medicines to South Africa.

British Columbia Adds Three Anti-Clotting Biosimilars To PharmaCare

British Columbia has added three new biosimilar versions of the anti-clotting drug enoxaparin to PharmaCare, including Redesca, Noromby and Inclunox. The move comes after the Canadian province recently included additional biosimilars in its switching program.

Topics

UsernamePublicRestriction

Register

GB151586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel